In the United States, dostarlimab is indicated for the treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.[5][6][8] Platinum-based agents such as cisplatin, carboplatin and oxaliplatin are mainstays of treatment when it comes to cancer chemotherapy treatment. It is also indicated for the treatment of solid tumors.<\/p>\n
In the European Union, dostarlimab is indicated as monotherapy for the treatment of adults with mismatch repair deficient (dMMR)\/microsatellite instability-high (MSI H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.<\/p>\n
In August 2021, the US Food and Drug Administration (FDA) granted accelerated approval to dostarlimab for adults with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.<\/p>\n
Dostarlimab was approved for the treatment of endometrial cancer in both the United States and the European Union in April 2021. Based on the Garnet trial, dostarlimab gained accelerated approval from the US Food and Drug Administration (FDA) in April 2021, and full approval in February 2023.<\/p>\n
If dostarlimab-gxly injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
JEMPERLI (dostarlimab-gxly) injection, for intravenous use Initial U.S. Approval: 2021<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":" Jemperli (dostarlimab) is a prescription medicine used to treat: Certain types of endometrial cancer (cancer of the womb) that are advanced or recurrent. Certain types of recurrent or advanced solid tumours.<\/p>\n DISEASE INDICATIONS-Gynaecological Cancer, Solid Tumor Summary of FDA-approved use on approval date: Click Here<\/a> If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cdostarlimab-gxly injection\u201d based on the information you provide.<\/p>\ndostarlimab-gxly injection
\nfor intravenous use Initial U.S. Approval: 2021<\/h2>\nFacts about dostarlimab-gxly injection<\/h4>\n
\nMANUFACTURER-GlaxoSmithKline
\nUSAGE-Intravenous
\nMEDICINE APPROVED BY-European Medical Agency (EMA),Food and Drug Administration (FDA)<\/p>\n
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n